GAITHERSBURG, MD, Jul 27, 2015 (Marketwired via COMTEX) -- Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, today announced that it has enrolled the first patient into a phase I clinical trial of HepTcell(TM) (FP-02.2), the company's immunotherapeutic compound to treat people chronically infected with the hepatitis B virus (HBV). The multi-center trial will be conducted at seven sites within the United Kingdom, and aims to recruit 72 patients with chronic HBV infection.
